Skip to content

Medical emergency? What to do

Molecular Markers Signal Early Metastases from Ocular Melanoma

3-RXPublished September 14, 20063 min read

Key points

  • Patients with melanoma of the eye are at risk for liver metastases, which are often not detected until they have turned into large, lethal tumors.
  • "The results show that we can pinpoint these molecular markers in the small amount of RNA and DNA obtained from fine needle biopsy," said principal investigator J.
  • Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.
  • Louis researchers first tested whether the minute quantities of RNA obtained from fine needle biopsies were adequate to detect the class 1 and class 2 signatures.

Patients with melanoma of the eye are at risk for liver metastases, which are often not detected until they have turned into large, lethal tumors. Now researchers have found molecular markers, including changes in a particular chromosome, that flag the presence of small metastases before they reach life-threatening size.

In a second important finding, the researchers showed that a common procedure, called fine needle biopsy, could be used to accurately detect these molecular signatures.

"The results show that we can pinpoint these molecular markers in the small amount of RNA and DNA obtained from fine needle biopsy," said principal investigator J. William Harbour, M.D., Associate Professor of Ophthalmology/Cell Biology/Medicine at Washington University School of Medicine in St. Louis.

"This means that testing for the markers is clinically feasible and could be used routinely to identify patients with ocular melanoma who are at high risk for metastasis."

Results were presented at the first meeting on Molecular Diagnostics in Cancer Therapeutic Development, organized by the American Association for Cancer Research.

In prior studies, Dr. Harbour and his colleagues found that a particular molecular signature—the pattern of expression, or activation, of a group of 3 to 10 genes—was an accurate predictor of metastasis. On the basis of this gene expression pattern, patients with ocular melanoma can now be divided into two groups: Those with a class 1 molecular signature have little risk of metastasis while those with a class 2 signature have a high risk.

In this study, the St. Louis researchers first tested whether the minute quantities of RNA obtained from fine needle biopsies were adequate to detect the class 1 and class 2 signatures. The results were positive. The signatures obtained from the fine needle biopsies corresponded to signatures obtained through conventional biopsies and to those found in the earlier studies.

Secondly, the researchers found that DNA from the fine needle biopsies included another biomarker: On chromosome 8, the loss of DNA in the p region correlated with time to metastasis. Among patients with 8p loss, the median time to metastasis was 25.8 months while for those without 8p loss, it was 37.4 months.

The authors conclude that RNA- and DNA-based testing of fine needle aspirates is clinically feasible and accurately predicts metastatic risk and time to metastasis in ocular melanoma.

The next step, Dr. Harbour said, is a larger, multicenter study in which cancer centers around the country will obtain fine needle aspirates from ocular melanoma patients and send them to Washington University for analysis. If this study confirms the usefulness of the procedure on a large scale, it could become routine practice.

Patients at high risk for metastasis could then opt for further, preventive treatment, including clinical trials of new targeted agents and immunotherapies, Dr. Harbour said.

"Because we can now identify high risk patients, we can design clinical trials specifically for this population," he said. "And this could lead to more rapid development of new agents to prevent or slow down metastasis in ocular melanoma."

Source: American Association for Cancer Research (AACR)

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underCancer

Keep reading

Brain

Italy court ruling links mobile phone use to tumor

Italy's supreme court has upheld a ruling that said there was a link between a business executive's brain tumor and his heavy mobile phone usage, potentially opening the door to further legal claims. The court's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.